Clinical Trial

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

Study acronym: FLUORO
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This single-arm phase II interventional study aims to assess disease response to, and toxicity of, a combination of obinutuzumab and atezolizumab, with or without radiotherapy, in treatment naive Follicular Lymphoma. The study will involve an induction phase and a maintenance phase for responding participants, for up to 24 months. Response to treatment will be monitored using medical imaging and clinical assessment.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2021-07-12; most recent amendment 2025-03-18.
Status change: Recruiting → Active, Not Recruiting 2023-01-13
Status change: Not Yet Recruiting → Recruiting 2021-08-18
Trial Details
NCT Number NCT04962126
Lead Sponsor Olivia Newton-John Cancer Research Institute
Collaborators: Roche Products Pty Limited, Austin Health, Ballarat Health Services
Conditions Follicular Lymphoma
Enrollment 15 participants
Start Date 2021-08-17
Primary Completion 2023-04-30 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2025-03-21